RNS Number : 8939Q
LungLife AI, INC
03 June 2024

LungLife AI, Inc.
("LungLife" or the "Company")

Confirmation of AGM

LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, confirms that its Annual General Meeting ("AGM") will be held at 4:00 P.M. (BST) on Wednesday 5 June 2024, at Investec Bank plc, 30 Gresham Street, London, EC2V 7QP.

For those shareholders who would like to dial into the meeting, please register by emailing LungLifeAI@walbrookpr.com or calling +44 (0)20 7933 8780 and the dial in link will be sent by email.

The results of voting on the resolutions will be announced via a regulatory information service and posted on the Company's website as soon as practicable after the AGM.

For further information please contact:

LungLife AI, Inc.	www.lunglifeai.com
Paul Pagano, CEO	**Via Walbrook PR**
David Anderson, CFO	
Investec Bank plc (Nominated Adviser & Broker)	**Tel: +44 (0)20 7597 5970**
Virginia Bull / Cameron MacRitchie / Lydia Zychowska	
Goodbody (Joint Broker)	**Tel: +44 (0) 20 3841 6202**
Tom Nicholson / Cameron Duncan	
Walbrook PR Limited	**Tel: +44 (0)20 7933 8780** or LungLifeAI@walbrookpr.com
Alice Woodings / Phillip Marriage	Mob: 07407 804 654 / 07867 984 082

About LungLife

LungLife AI is a developer of clinical diagnostic solutions designed to make a significant impact in the early detection of lung cancer, the deadliest cancer globally. Using a minimally invasive blood draw, the Company's LungLB® test is designed to deliver additional information to clinicians who are evaluating indeterminate lung nodules. For more information visit www.lunglifeai.com

Our Purpose is to be a driving force in the early detection to lung cancer. Our Vision is to invert the 20:80 ratio such that in years to come at least 80% of lung cancer is detected early.

END

NOABBGDLSSGDGSX